Gene
CDKN2B
CDKN2B is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (17), Actionable biomarkers (4), Trial mentions (6), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDKN2B. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
CDKN2B has 6 trial mentions across 4 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 14 of 11,460 | 0.12% |
| 2022 | 1 of 8,285 | 0.01% | 22 of 13,598 | 0.16% |
| 2021 | 0 of 8,692 | 0.00% | 28 of 15,045 | 0.19% |
| 2020 | 1 of 7,640 | 0.01% | 18 of 14,459 | 0.12% |
| 2019 | 2 of 7,300 | 0.03% | 23 of 12,159 | 0.19% |
| 2018 | 0 of 6,927 | 0.00% | 20 of 11,854 | 0.17% |
| 2017 | 0 of 6,558 | 0.00% | 20 of 11,595 | 0.17% |
Showing 10 of 37 years.
Assay-provider ledger (17)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 1 | June 01, 2026 |
| NanoString Technologies | Unclassified | Clinical validation | 1 | June 18, 2019 |
| Genomic Health | Diagnostic provider | Clinical validation | 1 | June 07, 2016 |
| Illumina | Unclassified | Clinical validation | 1 | May 30, 2014 |
| QIAGEN | Reagent supplier | Clinical validation | 1 | May 30, 2014 |
Showing 5 of 17 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDKN2B oncogenic mutation | Cdk4/6 Inhibitors | response-associated | glioma | Cancer Genome Interpreter |
| CDKN2B deletion | Cdk4/6 Inhibitors | response-associated | glioma | Cancer Genome Interpreter |
| CDKN2B oncogenic mutation | Cdk4/6 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| CDKN2B deletion | Cdk4/6 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05843253 | Trial eligibility (AACT) |
| NCT04145115 | Trial eligibility (AACT) |
| NCT05497076 | Trial eligibility (AACT) |
| NCT04040205 | Trial eligibility (AACT) |
| NCT04074785 | Trial eligibility (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (686)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abdominal Aortic Aneurysm | cardiovascular disease | GWAS credible sets |
| Abnormality of limbs | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Age-related cataract | disorder of visual system | GWAS credible sets |
| Agents acting on the renin-angiotensin system use measurement | measurement | GWAS credible sets |
Showing 5 of 686 associations.
Vendor sourcing (17)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.122A>G (p.N41S) alteration is located in exon 1 (coding exon 1) of the CDKN2B gene. This alteration results from a A to G substitution at nucleotide po... | View ClinVar record SCV003532277.3 |
| Fujian Cancer Hospital | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Age ≥18 when signing informed consent, both male and female; 2. Advanced or metastatic NSCLC confirmed by histology or cytology is stage IV according t... | View trial NCT05497076 |
| Fujian Cancer Hospital | Trial sponsor | Mentioned in trial textTrial free-text mention | CDKN2B | View trial NCT05497076 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The D86N variant in the CDKN2B gene has been reported previously as a germline variant in one individual with a metastatic pancreatic endocrine tumor (Lindbe... | View ClinVar record SCV000577028.4 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001076267.1 |
Showing 5 of 17 sourcing records.
Trial-cited literature (323)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. | Nature medicine | 2026 | 1 |
| Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy. | The New England journal of medicine | 2024 | 114 |
| First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | 50 |
| Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation. | Journal of translational medicine | 2024 | 4 |
| Knee Osteoarthritis: Epidemiology, Pathogenesis, and Mesenchymal Stem Cells: What Else Is New? An Update. | International journal of molecular sciences | 2023 | 293 |
Showing 5 of 323 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A23E | 1 | 2015 | PMID 25873077 |
| p.D86N | 2 | 2015 | PMID 25741868, PMID 25873077 |
| p.P16E | 1 | 2019 | PMID 31269959 |
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Mifepristone | Chemical | positive_correlate |
Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial. | 2023 |
| PROPRANOLOL | Chemical | positive_correlate |
Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. | 2010 |
| DEXAMETHASONE | Chemical | positive_correlate |
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. | 2010 |
| LENALIDOMIDE | Chemical | positive_correlate |
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. | 2010 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. | 2007 |
Showing 5 of 61 relation assertions.
Organizations publishing (382)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 15 | 2004 to 2026 |
| Dana-Farber Cancer Institute | Other | 13 | 2005 to 2022 |
| Novant Health | Hospital | 13 | 2012 to 2022 |
| University of London | Academic | 12 | 2007 to 2024 |
| The University of Texas System | Academic | 11 | 2004 to 2022 |
Showing 5 of 382 organizations.
Where CDKN2B appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
625 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.